Press Releases
March 19, 2024
Lupin Receives Approval from U.S. FDA for Aripiprazole Tablets, USP
March 15, 2024
Lupin Receives Approval from U.S. FDA for Doxycycline for Injection USP
February 16, 2024
Lupin Receives Approval from U.S. FDA for Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets)
February 15, 2024
Lupin Launches Ganirelix Acetate Injection in the United States
February 13, 2024
Lupin Launches Bromfenac Ophthalmic Solution, 0.075% in the United States
February 6, 2024
Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%
February 2, 2024
Lupin Launches Cyanocobalamin Nasal Spray in the United States
February 1, 2024
Lupin Receives Approval from U.S. FDA for Dronedarone Tablets, USP
January 23, 2024
Lupin Receives Tentative Approval from U.S. FDA for Rivaroxaban Tablets USP
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
Search Product

Global Privacy Control Detected
We have detected your Global Privacy Control (GPC) signal. In accordance with applicable privacy laws, we have automatically honored your preference and disabled all non-essential cookies and tracking.
Only necessary cookies required for the website to function are enabled.
Opt-Out Request Honored
We have respected your privacy preference. Your opt-out request through cookie settings or Global Privacy Control signal has been honored.
